Trial reportThe journal of nutrition, health & aging2010
Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile.
Trial report in The journal of nutrition, health & aging, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Multi-modal intervention to reduce cardiovascular risk among hypertensive older adults: Design of a randomized clinical trial.Contemporary clinical trials · 2015Trial
- Identification of Disease-Relevant, Sex-Based Proteomic Differences in iPSC-Derived Vascular Smooth Muscle Cells.International journal of molecular sciences · 2024Article
- Associations Between Hypertension, Angiotensin-Converting Enzyme Inhibitors, and Physical Performance in Very Old Adults: Results from the ilSIRENTE Study.The Journal of frailty & aging · 2024Article
- Is sarcopenia an associated factor of increased administration of specific medications in patients with heart failure? A systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2024Review
- Polypharmacy and Antibody Response to SARS-CoV-2 Vaccination in Residents of Long-Term Care Facilities: The GeroCovid Vax Study.Drugs & aging · 2023Article
- Article
- Sarcopenia and Cardiovascular Diseases.Circulation · 2023Review
- Prevalence of geriatric syndromes in frail patients and mortality risks.Frontiers in medicine · 2023Article
- Mini-review: Angiotensin- converting enzyme 1 (ACE1) and the impact for diseases such as Alzheimer's disease, sarcopenia, cancer, and COVID-19.Frontiers in aging · 2023Review
- Insulin-like growth factor-1 (IGF-1) as predictor of cardiovascular mortality in heart failure patients: data from the T.O.S.CA. registry.Internal and emergency medicine · 2022Article
- Sarcopenia: Diagnosis and Management, State of the Art and Contribution of Ultrasound.Journal of clinical medicine · 2021Review
- The Interactome in the Evolution From Frailty to Sarcopenic Dependence.Frontiers in cell and developmental biology · 2021Review
- Involvement of ACE2/Ang-(1-7)/MAS1 Axis in the Regulation of Ovarian Function in Mammals.International journal of molecular sciences · 2020Review
- Effect of Calcium and Vitamin D Supplements as an Adjuvant Therapy to Metformin on Menstrual Cycle Abnormalities, Hormonal Profile, and IGF-1 System in Polycystic Ovary Syndrome Patients: A Randomized, Placebo-Controlled Clinical Trial.Advances in pharmacological sciences · 2019Article
- Current IGFBP-Related Biomarker Research in Cardiovascular Disease-We Need More Structural and Functional Information in Clinical Studies.Frontiers in endocrinology · 2018Review
- Combined sprint and resistance training abrogates age differences in somatotropic hormones.PloS one · 2017Article
- Hypertension and aging.Ageing research reviews · 2016Review
- The renin-angiotensin system and prevention of age-related functional decline: where are we now?Age (Dordrecht, Netherlands) · 2015Review
- Optimizing the benefits of exercise on physical function in older adults.PM & R : the journal of injury, function, and rehabilitation · 2014Review
- Relationship between use of proton pump inhibitors and IGF system in older subjects.The journal of nutrition, health & aging · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
objectivesThe present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease.
designData are from the Trial of Angiotensin Converting Enzyme Inhibition and Novel Cardiovascular Risk Factors (TRAIN) study, a double-blind, crossover, randomized, placebo-controlled trial.
settingParticipants were recruited from the communities of Winston Salem, NC, and Greensboro, NC.
participantsSubjects > or = 55 years old with high cardiovascular disease risk profile.
interventionThe intervention consisted of 6-month administration of fosinopril vs. placebo. MEASUREMENTS: Serum concentrations of total IGF-1 and IGFBP-3 were measured in 100 participants of the TRAIN study at baseline, 6-month and 12-month follow-up visits. Differences in total IGF-1 and IGFBP-3 concentrations were assessed using two-sided paired ttests.
resultsThe mean age of participants (47% women) was 66.5 (standard deviation 7.2) years. Serum concentrations of total IGF-1 were significantly higher after 6-month treatment with fosinopril compared to placebo (203.73 ng/mL vs 194.24 ng/mL; p=0.02): After ACE-inhibitor intervention, significantly higher serum IGFBP-3 concentrations compared to controls (4308.81 ng/mL vs 4086.93 ng/mL; p=0.03) were also reported.
conclusionsA six-month treatment with fosinopril increases systemic levels of total IGF-1 and IGFBP-3 in older adults with high cardiovascular risk profile. This may represent a potential biological explanation to the beneficial effects of ACE-inhibition on stroke, ischemic heart disease and insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.